Skip to content

Immune Atlas of Anti-N-methyl-D-aspartate receptor encephalitis

Immune Atlas of Anti-N-methyl-D-aspartate receptor encephalitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300075420
Enrollment
Unknown
Registered
2023-09-05
Start date
2023-09-05
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune encephalitis

Interventions

Control group:NA

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Experimental group: ? Age 18 or above, but not exceeding 60 years old. ? Blood or cerebrospinal fluid (CSF) with anti-NMDAR titers greater than 11:1010, with positive results in both blood and CSF. ? Symptoms include abnormal behavior, cognitive impairment, speech disorders, seizures, involuntary movements, coma, central hypoventilation, etc. ? Duration of illness for at least six months, including relapsed patients (relapse defined as the emergence of new symptoms or worsening of symptoms after an initial improvement or stability for at least 2 months). ? Informed consent was obtained from patients and their relatives. Control group: ? Age 18 or above, but not exceeding 60 years old, with age and gender matching. ? Good general health, with a BMI between 18 and 34. ? Basic laboratory tests showing normal results. ? Blood or CSF with negative anti-NMDAR titers.

Exclusion criteria

Exclusion criteria: ? Patients diagnosed with epilepsy, traumatic brain injury, and/or other neurological disorders before the onset of encephalitis, as well as patients diagnosed with myocardial infarction, heart failure, liver diseases (such as cirrhosis, fatty liver, viral hepatitis), other autoimmune diseases excluding AE, and hematological disorders. ? Patients with pre-existing infections, along with bacterial, fungal, parasitic, or viral infections. ? Patients with concomitant tumors, excluding teratomas. ? Patients lacking crucial clinical data. ? Pregnant or breastfeeding patients.

Design outcomes

Primary

MeasureTime frame
differential expressed genes.;

Secondary

MeasureTime frame
Modified Rankin Scale;cognitive function score;Psychiatric scale score;Anxiety self-rating scale score;Depression self-rating scale score;GCS score;CAMS score;

Countries

China

Contacts

Public ContactHong Zhen

West China Hospital, Sichuan University

45713152@qq.com+86 28 8542 2549

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026